Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107223
Luis Otávio Nogueira, Dayany Leonel Boone
{"title":"Comment on “The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials”","authors":"Luis Otávio Nogueira, Dayany Leonel Boone","doi":"10.1016/j.parkreldis.2024.107223","DOIUrl":"10.1016/j.parkreldis.2024.107223","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107223"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107221
Shen-Yang Lim, Kai Bin Lim, Jia Wei Hor, Ai Huey Tan
{"title":"Authors' reply to “Perfection is the enemy of good - A Letter to the editor on \"Orthostatic hypotension in Parkinson's disease: Sit-to-stand vs. supine-to-stand protocol and clinical correlates”","authors":"Shen-Yang Lim, Kai Bin Lim, Jia Wei Hor, Ai Huey Tan","doi":"10.1016/j.parkreldis.2024.107221","DOIUrl":"10.1016/j.parkreldis.2024.107221","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107221"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107255
Jerry HK. Tan , Axel AS. Laurell , Emad Sidhom , James B. Rowe , John T. O'Brien
Co-morbid Alzheimer's disease (AD) pathology (amyloid-beta and tau) is commonly observed in Lewy body dementia (LBD), and this may affect clinical outcomes. A systematic review of the effect of AD co-pathology on longitudinal clinical outcomes in LBD was conducted. A search of MEDLINE and EMBASE (October 2024) yielded n = 3558 records that were screened by two independent reviewers. Included studies (n = 31) assessed AD co-pathology in LBD by neuropathologic examination (n = 10), positron emission tomography (PET) imaging (n = 7), cerebrospinal fluid (CSF) (n = 8) or plasma biomarkers (n = 6); and reported longitudinal clinical outcomes including cognitive and functional decline, mortality, or treatment response. Most neuropathology, PET and plasma studies reviewed demonstrated poorer prognosis in LBD + compared to LBD-, but discrepant findings were seen among CSF studies. No included study reported better outcomes in LBD+. The risk of bias was assessed with the Quality in Prognosis Studies tool. All studies rated as low risk of bias (n = 12) reported that the presence of AD co-pathology in LBD (LBD+) was associated with accelerated cognitive decline (n = 7/7), accelerated functional decline (n = 3/3), greater mortality (n = 2/2) and poorer response to treatment (n = 1/1). Among these studies, LBD+ was associated with an additional decline of −0.53 to −2.9 MMSE points/year compared to LBD-, while one study reported an adjusted hazard ratio for mortality in LBD + as 3.70. We conclude that AD co-pathology is associated with worse clinical outcomes in LBD whether assessed by greater cognitive decline, increased mortality or greater decline on functional assessment scales.
{"title":"The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review","authors":"Jerry HK. Tan , Axel AS. Laurell , Emad Sidhom , James B. Rowe , John T. O'Brien","doi":"10.1016/j.parkreldis.2024.107255","DOIUrl":"10.1016/j.parkreldis.2024.107255","url":null,"abstract":"<div><div>Co-morbid Alzheimer's disease (AD) pathology (amyloid-beta and tau) is commonly observed in Lewy body dementia (LBD), and this may affect clinical outcomes. A systematic review of the effect of AD co-pathology on longitudinal clinical outcomes in LBD was conducted. A search of MEDLINE and EMBASE (October 2024) yielded <em>n</em> = 3558 records that were screened by two independent reviewers. Included studies (n = 31) assessed AD co-pathology in LBD by neuropathologic examination (n = 10), positron emission tomography (PET) imaging (n = 7), cerebrospinal fluid (CSF) (n = 8) or plasma biomarkers (n = 6); and reported longitudinal clinical outcomes including cognitive and functional decline, mortality, or treatment response. Most neuropathology, PET and plasma studies reviewed demonstrated poorer prognosis in LBD + compared to LBD-, but discrepant findings were seen among CSF studies. No included study reported better outcomes in LBD+. The risk of bias was assessed with the Quality in Prognosis Studies tool. All studies rated as low risk of bias (<em>n</em> = 12) reported that the presence of AD co-pathology in LBD (LBD+) was associated with accelerated cognitive decline (<em>n</em> = 7/7), accelerated functional decline (<em>n</em> = 3/3), greater mortality (<em>n</em> = 2/2) and poorer response to treatment (<em>n</em> = 1/1). Among these studies, LBD+ was associated with an additional decline of −0.53 to −2.9 MMSE points/year compared to LBD-, while one study reported an adjusted hazard ratio for mortality in LBD + as 3.70. We conclude that AD co-pathology is associated with worse clinical outcomes in LBD whether assessed by greater cognitive decline, increased mortality or greater decline on functional assessment scales.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107255"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2025.107261
Hubert H. Fernandez (James and Constance Brown Endowed Chair for Movement Disorders)
{"title":"The alpha synuclein tug of war: A call for academic civility and open-mindedness","authors":"Hubert H. Fernandez (James and Constance Brown Endowed Chair for Movement Disorders)","doi":"10.1016/j.parkreldis.2025.107261","DOIUrl":"10.1016/j.parkreldis.2025.107261","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107261"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107227
Breno Kazuo Massuyama, Amanda Monteiro Viagi, Rafael Chaves Claudino de Queiroga, Raphael Pinheiro Camurugy da Hora, Victor Rebelo Procaci, Augusto Bragança Reis Rosa, Thiago Yoshinaga Tonholo Silva, Orlando Graziani Povoas Barsottini, José Luiz Pedroso
{"title":"NDUFAF5 variants cause early onset Leigh syndrome","authors":"Breno Kazuo Massuyama, Amanda Monteiro Viagi, Rafael Chaves Claudino de Queiroga, Raphael Pinheiro Camurugy da Hora, Victor Rebelo Procaci, Augusto Bragança Reis Rosa, Thiago Yoshinaga Tonholo Silva, Orlando Graziani Povoas Barsottini, José Luiz Pedroso","doi":"10.1016/j.parkreldis.2024.107227","DOIUrl":"10.1016/j.parkreldis.2024.107227","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107227"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107226
Filomena Abate , Francesca Di Biasio , Roberta Marchese , Tiziana Benzi Markushi , Andrea Ciammola , Nicola Ticozzi , Giovanna Calandra-Buonaura , Ilaria Cani , Luisa Sambati , Giovanni Fabbrini , Matteo Costanzo , Andrea Soricelli , Daniela Frosini , Eleonora Del Prete , Tommaso Schirinzi , Alessandro Stefani , Barbara Borroni , Alessandro Padovani , Paolo Barone , Marina Picillo , Laura De Togni
Background
Progressive Supranuclear Palsy (PSP) is a rare, heterogeneous neurodegenerative disease for which no treatment is currently available. In the context of clinical trials, the representativeness of the included patients is crucial for the generalizability of the results. Herein, we present results from a multicenter perspective study to identify the most restrictive criteria for patient selection and to assess the representativeness of eligible patients.
Methods
we enrolled 221 PSP patients diagnosed according to the MDS clinical criteria. All patients were screened with a set of inclusion and exclusion criteria based on previous and ongoing clinical trials in PSP and underwent motor and cognitive evaluation with the Montreal Cognitive Assessment battery and the PSP rating scale, respectively. Then, clinical features of eligible and non-eligible patients were compared at baseline and after 15,93 ± 8,77 months follow up.
Results
Eligible (28 patients, 12,6 %) patients were younger, showed shorter disease duration and lower severity but similar distribution of PSP phenotype and disease progression rates compared to non-eligible patients. The most restrictive non-modifiable criteria were independent gait, disease duration and cognitive status. Willingness to undergo lumbar puncture and treatment stability for previous 60 days represented potentially modifiable criteria.
Conclusion
Overall, PSP eligible for clinical trials are representative of the general PSP population. While motor and cognitive impairment represent the most important non-modifiable barriers to enter a clinical trial, other criteria as willingness to undergo lumbar puncture and treatment stability are potentially modifiable. Specific strategies are discussed to increase the number of eligible patients working on potentially modifiable criteria.
{"title":"Clinical trial eligibility in PSP: Population representativeness and potential criteria adjustment based on PSP-NET findings","authors":"Filomena Abate , Francesca Di Biasio , Roberta Marchese , Tiziana Benzi Markushi , Andrea Ciammola , Nicola Ticozzi , Giovanna Calandra-Buonaura , Ilaria Cani , Luisa Sambati , Giovanni Fabbrini , Matteo Costanzo , Andrea Soricelli , Daniela Frosini , Eleonora Del Prete , Tommaso Schirinzi , Alessandro Stefani , Barbara Borroni , Alessandro Padovani , Paolo Barone , Marina Picillo , Laura De Togni","doi":"10.1016/j.parkreldis.2024.107226","DOIUrl":"10.1016/j.parkreldis.2024.107226","url":null,"abstract":"<div><h3>Background</h3><div>Progressive Supranuclear Palsy (PSP) is a rare, heterogeneous neurodegenerative disease for which no treatment is currently available. In the context of clinical trials, the representativeness of the included patients is crucial for the generalizability of the results. Herein, we present results from a multicenter perspective study to identify the most restrictive criteria for patient selection and to assess the representativeness of eligible patients.</div></div><div><h3>Methods</h3><div>we enrolled 221 PSP patients diagnosed according to the MDS clinical criteria. All patients were screened with a set of inclusion and exclusion criteria based on previous and ongoing clinical trials in PSP and underwent motor and cognitive evaluation with the Montreal Cognitive Assessment battery and the PSP rating scale, respectively. Then, clinical features of eligible and non-eligible patients were compared at baseline and after 15,93 ± 8,77 months follow up.</div></div><div><h3>Results</h3><div>Eligible (28 patients, 12,6 %) patients were younger, showed shorter disease duration and lower severity but similar distribution of PSP phenotype and disease progression rates compared to non-eligible patients. The most restrictive non-modifiable criteria were independent gait, disease duration and cognitive status. Willingness to undergo lumbar puncture and treatment stability for previous 60 days represented potentially modifiable criteria.</div></div><div><h3>Conclusion</h3><div>Overall, PSP eligible for clinical trials are representative of the general PSP population. While motor and cognitive impairment represent the most important non-modifiable barriers to enter a clinical trial, other criteria as willingness to undergo lumbar puncture and treatment stability are potentially modifiable. Specific strategies are discussed to increase the number of eligible patients working on potentially modifiable criteria.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107226"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recent studies have reported that essential tremor (ET) presents with not only motor symptoms but also cognitive dysfunction. However, detailed pathological mechanisms remain unclear. Here, we evaluate the characteristics of cognitive changes in older patients.
Methods
Eighty-five patients aged 65 years or older with ET but without dementia were evaluated for cognitive function using the Addenbrooke Cognitive Examination Revised (ACE-R). The patients were compared with healthy controls (HCs), and the characteristics of cognitive dysfunction were examined. Age at onset and correlations with tremor severity were also investigated. Moreover, we performed resting-state network (RSNs) analysis in a subset of these patients, and the functional connectivity (FC) within the networks was compared with age-matched controls.
Results
Compared to HCs, older patients with ET showed a clear reduction in the total (p = 0.001), attention (p = 0.005), verbal fluency (p = 0.001), and memory (p = 0.001) ACE-R scores. Older-onset patients showed significant cognitive dysfunction compared with younger-onset patients. Verbal fluency correlated with tremor severity in the multiple regression analysis (p < 0.001). RSNs showed an increase in FC in the frontal lobes within the language network in patients with ET compared to HCs (p < 0.05, FWE-corrected).
Conclusion
Older patients with ET showed obvious cognitive dysfunction compared to HCs, indicating that cognitive dysfunction varies by age of onset and correlates with tremor severity. The results of the RSNs analysis suggest that the pathological mechanism of cognitive dysfunction in ET patients involves network changes similar to those in the early stages of Alzheimer's disease.
引言最近的研究表明，本质性震颤（ET）不仅表现为运动症状，还伴有认知功能障碍。然而，详细的病理机制仍不清楚。在此，我们评估了老年患者认知变化的特征：方法：我们使用 Addenbrooke 认知检查修订版（ACE-R）对 85 名 65 岁或以上的 ET 患者进行了认知功能评估。将患者与健康对照组（HCs）进行比较，并检查认知功能障碍的特征。我们还研究了发病年龄以及与震颤严重程度的相关性。此外，我们还对其中一部分患者进行了静息态网络（RSNs）分析，并将网络内的功能连通性（FC）与年龄匹配的对照组进行了比较：与对照组相比，老年 ET 患者的 ACE-R 总分（p = 0.001）、注意力（p = 0.005）、语言流畅性（p = 0.001）和记忆力（p = 0.001）明显下降。与年轻患者相比，老年患者表现出明显的认知功能障碍。在多元回归分析中，语言流畅性与震颤严重程度相关（p 结论：震颤严重程度与语言流畅性相关：与 HCs 相比，老年 ET 患者表现出明显的认知功能障碍，这表明认知功能障碍因发病年龄而异，并与震颤严重程度相关。RSNs 分析结果表明，ET 患者认知功能障碍的病理机制涉及与阿尔茨海默病早期阶段类似的网络变化。
{"title":"Evaluation of mild cognitive impairment in older patients with essential tremor","authors":"Miki Hashida , Satoshi Maesawa , Satomi Mizuno , Sachiko Kato , Yoshiki Ito , Manabu Mutoh , Takahiro Suzuki , Tomotaka Ishizaki , Takafumi Tanei , Takashi Tsuboi , Masashi Suzuki , Daisuke Nakatsubo , Takahiko Tsugawa , Epifanio Bagarinao , Toshihiko Wakabayashi , Masahisa Katsuno , Ryuta Saito","doi":"10.1016/j.parkreldis.2024.107228","DOIUrl":"10.1016/j.parkreldis.2024.107228","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent studies have reported that essential tremor (ET) presents with not only motor symptoms but also cognitive dysfunction. However, detailed pathological mechanisms remain unclear. Here, we evaluate the characteristics of cognitive changes in older patients.</div></div><div><h3>Methods</h3><div>Eighty-five patients aged 65 years or older with ET but without dementia were evaluated for cognitive function using the Addenbrooke Cognitive Examination Revised (ACE-R). The patients were compared with healthy controls (HCs), and the characteristics of cognitive dysfunction were examined. Age at onset and correlations with tremor severity were also investigated. Moreover, we performed resting-state network (RSNs) analysis in a subset of these patients, and the functional connectivity (FC) within the networks was compared with age-matched controls.</div></div><div><h3>Results</h3><div>Compared to HCs, older patients with ET showed a clear reduction in the total (<em>p</em> = 0.001), attention (<em>p</em> = 0.005), verbal fluency (<em>p</em> = 0.001), and memory (<em>p</em> = 0.001) ACE-R scores. Older-onset patients showed significant cognitive dysfunction compared with younger-onset patients. Verbal fluency correlated with tremor severity in the multiple regression analysis (<em>p</em> < 0.001). RSNs showed an increase in FC in the frontal lobes within the language network in patients with ET compared to HCs (<em>p</em> < 0.05, FWE-corrected).</div></div><div><h3>Conclusion</h3><div>Older patients with ET showed obvious cognitive dysfunction compared to HCs, indicating that cognitive dysfunction varies by age of onset and correlates with tremor severity. The results of the RSNs analysis suggest that the pathological mechanism of cognitive dysfunction in ET patients involves network changes similar to those in the early stages of Alzheimer's disease.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107228"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107245
Kevin Duff , Julia V. Vehar , Daniel Weintraub
Introduction
Although practice effects (PE) on repeated cognitive testing have received growing interest in Alzheimer's disease, they have been understudied in Parkinson's disease (PD). The current paper examined PE across one week in a sample of patients with PD via traditional methods and regression-based change scores, as well as if these change scores relate to clinical variables in PD.
Methods
Thirty-five patients with PD were administered a brief cognitive battery twice across approximately one week. Using both simple-difference and standardized regression-based change scores, a series of one-sample and independent t-tests were calculated to assess for PE across the test battery. Pearson correlations examined both types of change scores and measures of mood and severity of motor symptoms.
Results
Whereas traditional analyses (i.e., simple difference scores and dependent t-tests) did not reveal any changes on test scores over this interval, regression-based change scores did identify that these individuals showed significantly smaller-than-expected PE on three of the seven cognitive scores. Furthermore, when these regression-based change scores were trichotomized (decline/stable/improve), four of the seven tests showed significantly more decline than expected in this sample. Finally, these regression-based change scores significantly correlated with motor measures, with smaller PE being associated with worse motor functioning.
Conclusion
Although these results are preliminary and need to be replicated in larger and more diverse samples, smaller-than-expected PE are seen in PD and they may signal more advanced disease.
{"title":"Short-term cognitive practice effects in Parkinson's disease: More than meets the eye","authors":"Kevin Duff , Julia V. Vehar , Daniel Weintraub","doi":"10.1016/j.parkreldis.2024.107245","DOIUrl":"10.1016/j.parkreldis.2024.107245","url":null,"abstract":"<div><h3>Introduction</h3><div>Although practice effects (PE) on repeated cognitive testing have received growing interest in Alzheimer's disease, they have been understudied in Parkinson's disease (PD). The current paper examined PE across one week in a sample of patients with PD via traditional methods and regression-based change scores, as well as if these change scores relate to clinical variables in PD.</div></div><div><h3>Methods</h3><div>Thirty-five patients with PD were administered a brief cognitive battery twice across approximately one week. Using both simple-difference and standardized regression-based change scores, a series of one-sample and independent <em>t-</em>tests were calculated to assess for PE across the test battery. Pearson correlations examined both types of change scores and measures of mood and severity of motor symptoms.</div></div><div><h3>Results</h3><div>Whereas traditional analyses (i.e., simple difference scores and dependent <em>t</em>-tests) did not reveal any changes on test scores over this interval, regression-based change scores did identify that these individuals showed significantly smaller-than-expected PE on three of the seven cognitive scores. Furthermore, when these regression-based change scores were trichotomized (decline/stable/improve), four of the seven tests showed significantly more decline than expected in this sample. Finally, these regression-based change scores significantly correlated with motor measures, with smaller PE being associated with worse motor functioning.</div></div><div><h3>Conclusion</h3><div>Although these results are preliminary and need to be replicated in larger and more diverse samples, smaller-than-expected PE are seen in PD and they may signal more advanced disease.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107245"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.parkreldis.2024.107219
Megan Rose Readman , Yang Wang , Fang Wan , Ian Fairman , Sally A. Linkenauger , Trevor J. Crawford , Christopher J. Plack
Background
Hearing impairment is implicated as a risk factor for Parkinson's disease (Parkinson's) incidence, with evidence suggesting that clinically diagnosed hearing loss increases Parkinson's risk 1.5–1.6 fold over 2–5 years follow up. However, the evidence is not unanimous with additional studies observing that self-reported hearing capabilities do not significantly influence Parkinson's incidence. Thus, additional cohort analyses that draw on alternative auditory measures are required to further corroborate the link between Parkinson's and hearing impairment.
Objectives
To determine whether hearing impairment, estimated using a speech-in-noise test (the Digit Triplet Test, DTT), is a risk factor for Parkinson's incidence.
Methods
This was a pre-registered prospective cohort study using data from the UK Biobank. Data pertaining to 159,395 individuals, who underwent DTT testing and were free from Parkinson's at the point of assessment, were analysed. A Cox Proportional Hazard model, controlling for age, sex and educational attainment was conducted.
Results
During a median follow up of 14.24 years, 810 cases of probable Parkinson's were observed. The risk of incident Parkinson's increased with baseline hearing impairment [hazard ratio: 1.57 (95%CI: 1.018, 2.435; P = .041)], indicating 57 % increase in risk for every 10 dB increase in speech-reception threshold (SRT). However, when hearing impairment was categorised in accordance with UK Biobank SRT norms neither ‘Insufficient’ nor ‘Poor’ hearing significantly influenced Parkinson's risk compared to ‘Normal’ hearing.
Conclusions
The congruence of these findings with prior research further supports the existence of a relationship between hearing impairment and Parkinson's incidence.
{"title":"Speech-in-noise hearing impairment is associated with increased risk of Parkinson's: A UK biobank analysis","authors":"Megan Rose Readman , Yang Wang , Fang Wan , Ian Fairman , Sally A. Linkenauger , Trevor J. Crawford , Christopher J. Plack","doi":"10.1016/j.parkreldis.2024.107219","DOIUrl":"10.1016/j.parkreldis.2024.107219","url":null,"abstract":"<div><h3>Background</h3><div>Hearing impairment is implicated as a risk factor for Parkinson's disease (Parkinson's) incidence, with evidence suggesting that clinically diagnosed hearing loss increases Parkinson's risk 1.5–1.6 fold over 2–5 years follow up. However, the evidence is not unanimous with additional studies observing that self-reported hearing capabilities do not significantly influence Parkinson's incidence. Thus, additional cohort analyses that draw on alternative auditory measures are required to further corroborate the link between Parkinson's and hearing impairment.</div></div><div><h3>Objectives</h3><div>To determine whether hearing impairment, estimated using a speech-in-noise test (the Digit Triplet Test, DTT), is a risk factor for Parkinson's incidence.</div></div><div><h3>Methods</h3><div>This was a pre-registered prospective cohort study using data from the UK Biobank. Data pertaining to 159,395 individuals, who underwent DTT testing and were free from Parkinson's at the point of assessment, were analysed. A Cox Proportional Hazard model, controlling for age, sex and educational attainment was conducted.</div></div><div><h3>Results</h3><div>During a median follow up of 14.24 years, 810 cases of probable Parkinson's were observed. The risk of incident Parkinson's increased with baseline hearing impairment [hazard ratio: 1.57 (95%CI: 1.018, 2.435; <em>P</em> = .041)], indicating 57 % increase in risk for every 10 dB increase in speech-reception threshold (SRT). However, when hearing impairment was categorised in accordance with UK Biobank SRT norms neither ‘Insufficient’ nor ‘Poor’ hearing significantly influenced Parkinson's risk compared to ‘Normal’ hearing.</div></div><div><h3>Conclusions</h3><div>The congruence of these findings with prior research further supports the existence of a relationship between hearing impairment and Parkinson's incidence.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"131 ","pages":"Article 107219"},"PeriodicalIF":3.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142966290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-31DOI: 10.1016/j.parkreldis.2025.107300
Francesca Mameli , Edoardo Nicolò Aiello , Fabiana Ruggiero , Eleonora Zirone , Linda Borellini , Filippo Cogiamanian , Angelica Marfoli , Federica Solca , Barbara Poletti , Nicola Ticozzi , Sergio Barbieri , Alberto Priori , Roberta Ferrucci
Introduction
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves motor functions in patients with Parkinson's disease (PD) but may cause a decline in specific cognitive domains including executive processes and language.
The aim of this study was to derive standardized regression-based (SRB) reliable change indices (RCIs) in an Italian cohort of Parkinson's patients undergoing STN-DBS to detect clinically meaningful variations in verbal fluency (VF) one year after surgery define.
Methods
Before (T0) and 12 months after (T1) surgery, 36 PD patients who underwent bilateral STN-DBS were evaluated with the Alternate Verbal Fluency Battery (AVFB), including phonemic (PVF), semantic (SVF) and alternate VF tests (AVF) and a composite shifting index (CSI). At T0, motor status was assessed using the Unified Parkinson's Disease Rating Scale-III (UPDRS-III) and L-dopa equivalent daily dose was recorded.
Results
Group-level declines were limited to PVF and SVF scores. Applications of these RCIs revealed idiosyncratic patterns of longitudinal trends that differed from those at the group level. Indeed, when looking at individual performances, no clustered pattern of decline or improvement could be visibly detected. The UPDRS-III predicted T1 AVF and CSI scores.
Conclusion
Our study provides Italian practitioners and researchers with SRB-RCIs to detect meaningful differences in the VF performance of PD patients undergoing STN-DBS one year after surgery. Variables associated with postoperative cognitive changes can be used in future studies to develop multivariable predictive models to support clinical decision making and patient counselling.
{"title":"Regression-based thresholds to detect clinical changes in verbal fluency after STN-DBS in Parkinson's disease","authors":"Francesca Mameli , Edoardo Nicolò Aiello , Fabiana Ruggiero , Eleonora Zirone , Linda Borellini , Filippo Cogiamanian , Angelica Marfoli , Federica Solca , Barbara Poletti , Nicola Ticozzi , Sergio Barbieri , Alberto Priori , Roberta Ferrucci","doi":"10.1016/j.parkreldis.2025.107300","DOIUrl":"10.1016/j.parkreldis.2025.107300","url":null,"abstract":"<div><h3>Introduction</h3><div>Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves motor functions in patients with Parkinson's disease (PD) but may cause a decline in specific cognitive domains including executive processes and language.</div><div>The aim of this study was to derive standardized regression-based (SRB) reliable change indices (RCIs) in an Italian cohort of Parkinson's patients undergoing STN-DBS to detect clinically meaningful variations in verbal fluency (VF) one year after surgery define.</div></div><div><h3>Methods</h3><div>Before (T0) and 12 months after (T1) surgery, 36 PD patients who underwent bilateral STN-DBS were evaluated with the Alternate Verbal Fluency Battery (AVFB), including phonemic (PVF), semantic (SVF) and alternate VF tests (AVF) and a composite shifting index (CSI). At T0, motor status was assessed using the Unified Parkinson's Disease Rating Scale-III (UPDRS-III) and L-dopa equivalent daily dose was recorded.</div></div><div><h3>Results</h3><div>Group-level declines were limited to PVF and SVF scores. Applications of these RCIs revealed idiosyncratic patterns of longitudinal trends that differed from those at the group level. Indeed, when looking at individual performances, no clustered pattern of decline or improvement could be visibly detected. The UPDRS-III predicted T1 AVF and CSI scores.</div></div><div><h3>Conclusion</h3><div>Our study provides Italian practitioners and researchers with SRB-RCIs to detect meaningful differences in the VF performance of PD patients undergoing STN-DBS one year after surgery. Variables associated with postoperative cognitive changes can be used in future studies to develop multivariable predictive models to support clinical decision making and patient counselling.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"132 ","pages":"Article 107300"},"PeriodicalIF":3.1,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143099992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号